1M6MYTD1A5AMAX
Caricamento quotazioni...
Previsioni
| Acquista |
1 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Aclarion: scan volume H1 2026 up 141%
Aclarion reports scan‑volume growth of 141% year‑on‑year and 71% sequentially for the first half of 2026, driven by rising adoption of the Nociscan platform. As of 30 June the company had USD 16.3 million in cash and was debt‑free; management says funds will last into H2 2027. Aclarion secured reimbursement from three major UK private insurers (Vitality, Axa, Aviva) and has launched a US market‑access program with PRIA Healthcare. The CLARITY study was expanded and a first interim readout is expected in 2026; the patent portfolio now comprises 65 granted and pending patents worldwide. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 22,09K | 34,76% |
| Utile lordo | 7,27K | 66,71% |
| Utile netto | -2,41 Mln | 77,26% |
| EBITDA | -2,35 Mln | 79,15% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,19 Mln € |
Numero di azioni | 533,31K |
Massimo/minimo a 52 settimane | 10,37 € - 1,68 € |
| Dividendi | No |
Beta | 1,24 |
Rapporto P/E | -0,34 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,38 |
Rapporto P/S | 16,55 |
Profilo aziendale
| Nome | ACLARION NEW DL-,00001 |
| CEO | Brent Ness |
| Dipendenti | 11 |
